FDA happenings: More QC troubles at Guidant; Label expansion for Medtronic CRTs; FDA announces Critical Path opportunities list; and more Around the industry: Boston Scientific-Guidant merger cleared by FTC; Guidant suspends use of Xience V; Conor licenses pimecrolimus from Novartis; and more Proceedings of TCT 3, 21-24 (2006). view PDF
-
Subscribe
Subscribed
Already have a WordPress.com account? Log in now.
Fluent in Science 